Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Operating Expenses: 2023-2025

Historic Operating Expenses for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to $64.0 million.

  • Day One Biopharmaceuticals' Operating Expenses fell 0.12% to $64.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.3 million, marking a year-over-year decrease of 4.50%. This contributed to the annual value of $348.4 million for FY2024, which is 69.09% up from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Operating Expenses is $64.0 million, which was down 7.02% from $68.9 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Operating Expenses ranged from a high of $123.0 million in Q2 2024 and a low of $45.9 million during Q2 2023.
  • For the 3-year period, Day One Biopharmaceuticals' Operating Expenses averaged around $71.0 million, with its median value being $65.4 million (2024).
  • In the last 5 years, Day One Biopharmaceuticals' Operating Expenses surged by 168.23% in 2024 and then plummeted by 44.00% in 2025.
  • Day One Biopharmaceuticals' Operating Expenses (Quarterly) stood at $59.5 million in 2023, then soared by 58.85% to $94.5 million in 2024, then declined by 0.12% to $64.0 million in 2025.
  • Its Operating Expenses stands at $64.0 million for Q3 2025, versus $68.9 million for Q2 2025 and $71.8 million for Q1 2025.